Resources

This quick reference guide provides information for approved providers of residential aged care to understand and meet their obligations to collect and report data on incontinence care for the QI Program.

This quick reference guide provides information for approved providers of residential aged care to understand and meet their obligations to collect and report data on hospitalisation for the QI Program.

This poster outlines the National Aged Care Mandatory Quality Indicator Program (QI Program) quality indicators.

This arrangement has been developed to facilitate efforts towards nationally consistent radiation safety regulatory frameworks and radiation health outcomes.

This fact sheet for providers outlines the changes to human papillomavirus (HPV) vaccination under the National Immunisation Program (NIP) in 2023.

This framework outlines the National Mental Health Workforce Strategy.

This checklist is for residential aged care providers and their staff, and provides reminders on how to prepare and respond to a COVID-19 positive case or outbreak.

This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This PNH review considered eculizumab. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This infographic issued on 3 February 2023 provides a weekly traffic light report of the coronavirus (COVID-19) situation across Australia.

COVID-19 vaccination – Geographic vaccination rates (LGA) – 2 February 2023

This weekly report provides a snapshot of data on the impact of COVID-19 in residential aged care facilities nationally. The report includes data on the number of services impacted and number of staff and resident cases, as well as workforce, testing and PPE provided to affected services.

This report is a snapshot of feedback taken from our community consultation (between October 2021 to January 2022). Sector insights were sought to improve quality and safety for sector participants and consumers, while removing barriers for providers and workers.

This MPS VI review considered galsulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

This MPS VI review considered galsulfase. The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations.

This HT1 review considered nitisinone (only the brand Orfadin® was in scope for the review). The Expert Panel considered this review at its October 2020 meeting. This document provides a summary of the review findings and recommendations in plain English for health consumers.

Social tiles and suggested captions that you could use across your social media platforms. This content can be adapted in order to tailor it to your audience.

We will undertake consultation in 2023 to inform the design of the new in-home aged care program. This calendar lets you know when these activities are happening.

This fact sheet describes the steps you should take in the first 24 hours following the identification of acute respiratory infections or outbreaks in residential aged care homes.

This document contains the terms of reference for the Intellectual Disability Health Education and Training Expert Advisory Group.

This report outlines the pre-listing assessment framework and governance structure for the Prostheses List. It also addresses Ernst & Young, and Adelaide Health Technology Assessment options and recommendations.